You are here

LogicBio Therapeutics Appoints Kenneth Huttner, M.D., Ph.D., as Senior Vice President, Head of Clinical Development

CAMBRIDGE, Mass., Feb. 22, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (NASDAQ:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases, today announced the appointment of Kenneth Huttner, M.D., Ph.D., as Senior Vice President, Head of Clinical Development. Dr. Huttner brings over 15 years of clinical research and development and translational medicine experience to the LogicBio leadership team, as well as a clinical background in pediatrics and neonatology.
Friday, February 22, 2019 - 07:00